Frontlight ResearchEarly access
WithdrawnNo phase
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
Key facts
- Who runs it
- Guangzhou Bio-gene Technology Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 31 Aug 2025
- Ended
- 2 Mar 2026
- Type of study
- Interventional
- Treatments tested
- CAR-T
- Record updated
- 28 May 2026
- Why it stopped
- Due to corporate strategic adjustment.
Who can take part
- Age
- 1 year to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- The patient fully understands the study procedures and voluntarily signs the informed consent form
- Patients diagnosed with tumors that demonstrate positive B7H3 expression in tumor tissues as confirmed by immunohistochemistry (IHC)
- Presence of at least one extracranial lesion that is measurable according to the RECIST 1.1 criteria
- Estimated survival duration of ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1 at baseline
- Recovery from prior treatment-related toxicities to a level below Grade 2
- Adequate hematopoietic and organ function without severe impairment
- Availability of suitable venous access for leukapheresis, with no contraindications to the collection of white blood cells
Who cannot take part
- History of severe allergic reactions or known hypersensitivity to any component of the investigational drugs used in the study
- Receipt of (attenuated) live vaccines within 4 weeks prior to screening
- Patients with a history of or currently diagnosed with other malignant tumors
- Presence of brain metastases or clinically significant central nervous system (CNS) disorders
- HIV+,HBV,HCV,EBV,CMV
- Positive T-cell interferon-gamma release assay or sputum smear for tuberculosis
- Documented history or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or significant pulmonary dysfunction
- Severe cardiovascular disease or uncontrolled refractory hypertension, unless deemed stable and non-interfering with the study by the investigator
- Active autoimmune or inflammatory neurological disorders
- Presence of uncontrolled infections requiring systemic antibiotic, antifungal, or antiviral therapy
- Individuals with a history of alcohol dependence or substance abuse
- Prior treatment within 14 days or five half-lives (whichever is longer) before blood collection for CAR-T preparation that may interfere with lymphocyte expansion
- Severe hepatic or renal dysfunction, or presence of altered mental status
- Pregnant or lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid tumors.
Read full original descriptionShow less
Eligible subjects are followed until 12 months after infusion or until meeting treatment withdrawal criteria, whichever occurs first.
The group in the trial
- CAR-TTreatment being tested
The administration can be performed via intravenous infusion, either as a single dose or multiple doses, at a dosage ranging from 3×10⁶ to 1×10⁷ CAR-positive T cells per kilogram of body weight, with an allowable deviation of ±20%.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study Evaluating the Safety and Efficacy of B7H3 CAR-T Cell Therapy in Patients With B7H3-Positive Solid Tumors
- Record updated
- 28 May 2026